Wednesday, August 16, 2017 -- Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) both cause a progressive loss of brain cells that scientists have so far failed to prevent. A Genentech-led team of academic and industry researchers has discovered a protein that, when blocked, reverses a signaling pathway that causes neurodegeneration in these conditions.
Wednesday, August 16, 2017 -- Mitsubishi Tanabe Pharma America Inc. of New Jersey has reported that Radicava (edaravone), an intravenous therapy for adults with amyotrophic lateral sclerosis (ALS), is now available in the U.S.This product represents the first ALS treatment approved by the U.S. Food and Drug Administration in over 20 years. Company spokespersons reported that Radicava can slow down the rate of physical decline in ALS patients by up to 33 percent."After 13 years of clinical research and investment, we have reached a seminal moment, which may shift the treatment paradigm for this terrible disease," Tom Larson, chief commercial officer for Mitsubishi Tanabe Pharma America, said. "As of today, all across the country, conversations between ALS specialists and patients may be substantially different.
Tuesday, August 15, 2017 -- An emerging larger animal model aims to bridge the gap between mouse and man, facilitating the development of therapies for ALS.
Wednesday, August 16, 2017 -- A team led by scientists at St. Jude Children's Research Hospital and Mayo Clinic has identified a basic biological mechanism that kills neurons in amyotrophic lateral sclerosis (ALS) and in a related genetic disorder, frontotemporal dementia (FTD), found in some ALS patients.